These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 7625006)

  • 1. [Combined heparinization during hemosorption].
    Marochkov AV; Burakovskiĭ NI
    Vestn Khir Im I I Grek; 1994; 153(7-12):113-5. PubMed ID: 7625006
    [No Abstract]   [Full Text] [Related]  

  • 2. [Controlled heparinization during hemosorption].
    Marochkov AV; Iurchenko AA; Kravtsov NN
    Vestn Khir Im I I Grek; 1985 Mar; 134(3):101-3. PubMed ID: 4002508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomograms for the administration of unfractionated heparin.
    Grubb H; Lovett J; Kingman HM; Copplestone JA; Prentice AG
    Thromb Haemost; 2001 Mar; 85(3):565. PubMed ID: 11307835
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of a sliding scale protocol for heparin on the ability to maintain whole blood activated partial thromboplastin times within a desired range in hemodialysis patients.
    Low CL; Bailie G; Morgan S; Eisele G
    Clin Nephrol; 1996 Feb; 45(2):120-4. PubMed ID: 8846524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effects of hemosorption and combined therapy on cerebral perfusion pressure in patients with severe craniocerebral trauma].
    Isaev IuV; Dhangirova GM; Bichurina VA; Asriiants SIu; Poliakh VF; Fedorova VIu; Shadrin AG
    Anesteziol Reanimatol; 1997; (6):46-7. PubMed ID: 9511247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Evaluation of the adequacy of heparin administration during hemosorption].
    Iunovidova LI; Lekhtman AM; Levantovskaia OM
    Khirurgiia (Mosk); 1990 Jun; (6):85-8. PubMed ID: 2214584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of the activated partial thromboplastin time for heparin monitoring.
    Smythe MA; Koerber JM; Westley SJ; Nowak SN; Begle RL; Balasubramaniam M; Mattson JC
    Am J Clin Pathol; 2001 Jan; 115(1):148-55. PubMed ID: 11190801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of weight, sex, age, clinical diagnosis, and thromboplastin reagent on steady-state intravenous heparin requirements.
    White RH; Zhou H; Woo L; Mungall D
    Arch Intern Med; 1997 Nov; 157(21):2468-72. PubMed ID: 9385298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving use of heparin in acute deep venous thrombosis.
    Gold JA; Ferguson CJ; Williams NF; Braun SK
    Wis Med J; 1996 May; 95(5):311-2. PubMed ID: 8936037
    [No Abstract]   [Full Text] [Related]  

  • 10. [A new test for monitoring heparin therapy].
    Camici M; Evangelisti L; Giordani R
    Minerva Med; 1998 Sep; 89(9):345-9. PubMed ID: 9856125
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Monitoring blood coagulation].
    Pabinger-Fasching I
    Wien Med Wochenschr; 1999; 149(2-4):70-1. PubMed ID: 10378328
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reactivation of coagulation after stopping infusions of recombinant hirudin and unfractionated heparin in unstable angina and myocardial infarction without ST elevation: results of a randomized trial. OASIS Pilot Study Investigators. Organization to Assess Strategies for Ischemic++ Syndromes.
    Flather MD; Weitz JI; Yusuf S; Pogue J; Sussex B; Campeau J; Gill J; Schuld R; Joyner CD; Morris AL; Lai C; Théroux P; Marquis JF; Chan YK; Venkatesh G; Jessel A
    Eur Heart J; 2000 Sep; 21(17):1473-81. PubMed ID: 10952840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Laboratory monitoring of heparin therapy.
    Wittkowsky AK
    Clin Pharm; 1991 Nov; 10(11):824. PubMed ID: 1794218
    [No Abstract]   [Full Text] [Related]  

  • 14. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?].
    Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J
    Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of deep venous thrombosis].
    Mesters RM
    Internist (Berl); 1999 Oct; 40(10):1098-9. PubMed ID: 10610366
    [No Abstract]   [Full Text] [Related]  

  • 16. Subcutaneous unfractionated heparin for the treatment of venous thromboembolism.
    Kearon C
    Curr Opin Pulm Med; 2007 Sep; 13(5):398-402. PubMed ID: 17940484
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hemosorption using xenogeneic spleen in the combined detoxication therapy of complicated trauma].
    Grinev MV; Tsibin IuN; Frolov GM; Tarelkina MN; Pivovarova LP
    Ortop Travmatol Protez; 1988 May; (5):6-10. PubMed ID: 3174105
    [No Abstract]   [Full Text] [Related]  

  • 19. Practical approach to anticoagulation for cardiopulmonary bypass in the patient with congenital prolonged activated partial thromboplastin time.
    Cankovic L; Steenwyk BL; McGiffin DC; Nielsen VG
    Blood Coagul Fibrinolysis; 2008 Oct; 19(7):725-6. PubMed ID: 18832918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic effects of early administration of low-dose heparin in patients with severe sepsis].
    Zhang XJ; Ma XC
    Zhonghua Wai Ke Za Zhi; 2006 Sep; 44(17):1209-11. PubMed ID: 17147870
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.